Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurological Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CDKL1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDKL1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. |
View CDKL1 Products |
| Gene Delivery | CDKL1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for cell-based target engagement assays. |
View CDKL1 Products |
| Benchmark Ab | Anti-CDKL1 Recombinant Antibody Recombinant positive control for Western Blot, ELISA, and IP validation. |
View CDKL1 Products |
| Validator | CDKL1 siRNA Set For target knockdown verification and phenotypic assay validation. |
View CDKL1 Products |
| Related Target A | CDKL5 High-homology family member. Crucial counter-screening target to ensure drug selectivity. |
View CDKL5 Products |
| Related Target B | CDK2 Key cell cycle regulator. Essential off-target screening partner for cyclin-dependent kinase inhibitors. |
View CDK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity & Profiling | High-purity CDKL1, CDKL5, and CDK2 proteins available for robust side-by-side ATP-competitive inhibition assays. |
| Intracellular Target Engagement | Premade Lentiviral Particles optimized for high-efficiency transduction to build stable cell lines for NanoBRET or cellular thermal shift assays (CETSA). |
| Lack of Specific Controls | Sequence-verified recombinant benchmark antibodies and validated siRNA knockdown pools included to eliminate false positives. |
| Assay Reproducibility | Strict batch-to-batch consistency with sequence verification, high purity (>95%), and precise endotoxin control. |
Live CDKL1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic interest in CDKL1 (Cyclin-Dependent Kinase-Like 1) is growing rapidly as oncology research shifts from broad-spectrum pan-CDK inhibitors to highly selective cell cycle modulators. CDKL1 is frequently overexpressed in various human cancers, including colorectal cancer, breast cancer, and glioblastoma, where it drives cell proliferation and suppresses apoptosis. As first-generation CDK inhibitors encounter limitations due to dose-limiting toxicities (such as myelosuppression), the next wave of drug discovery is focused on achieving precise isoform and family-level selectivity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Colorectal Cancer, Glioblastoma, Breast Cancer | Kinase Selectivity Profiling (Need high-purity CDKL1 vs. CDK2/CDKL5 panel) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Refractory Solid Tumors | Ubiquitination & Degradation Kinetics (Need Lentivirus for stable reporter cell lines) |
| RNA Therapeutics | RNAi Developers | Undruggable Oncogenic Pathways | In vitro Knockdown Validation (Need sequence-verified siRNA and Western-grade antibodies) |